✦ LIBER ✦

579 Cytotoxic effects of resveratrol on imatinib sensitive and resistant K562 chronic myeloid leukemia cells

✍ Scribed by G. Can; Y. Baran

Book ID: 119602360
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 47 KB
Volume: 8
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(10)71380-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Differential sensitivity to resveratrol-

Differential sensitivity to resveratrol-induced apoptosis of human chronic myeloid (K562) and acute lymphoblastic (HSB-2) leukemia cells

✍ Carla Luzi; Fabrizia Brisdelli; Benedetta Cinque; Grazia Cifone; Argante Bozzi 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 284 KB

Effects of carboxyamidotriazole on in vi

Effects of carboxyamidotriazole on in vitro models of imatinib-resistant chronic myeloid leukemia

✍ Riccardo Alessandro; Simona Fontana; Margherita Giordano; Chiara Corrado; Paolo 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 468 KB

## Abstract Although imatinib mesylate (IM) has revolutionized the treatment of chronic myeloid leukemia (CML), some patients develop resistance with progression of leukemia. Alternative or additional targeting of signaling pathways deregulated in bcr‐abl‐driven CML cells may provide a feasible opt

Contribution of BCR–ABL-independent acti

Contribution of BCR–ABL-independent activation of ERK1/2 to acquired imatinib resistance in K562 chronic myeloid leukemia cells

✍ Takeru Nambu; Norie Araki; Aiko Nakagawa; Akihiko Kuniyasu; Tatsuya Kawaguchi; A 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 502 KB

Synergistic cytotoxicity of AZT plus alp

Synergistic cytotoxicity of AZT plus alpha and gamma interferon in chronic myeloid leukemia cell line K562

✍ Patrizia Tosi; Giuseppe Visain; Emanuela Ottaviani; Barbara Gamberi; Annarita Ce 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 448 KB

NF-κB inhibition triggers death of imati

NF-κB inhibition triggers death of imatinib-sensitive and imatinib-resistant chronic myeloid leukemia cells including T315I Bcr-Abl mutants

✍ Nadia Lounnas; Catherine Frelin; Nadège Gonthier; Pascal Colosetti; Anne Sirvent 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 French ⚖ 521 KB

## Abstract The Bcr‐Abl inhibitor imatinib is the current first‐line therapy for all newly diagnosed chronic myeloid leukemia (CML). Nevertheless, resistance to imatinib emerges as CML progresses to an acute deadly phase implying that physiopathologically relevant cellular targets should be validat

Cytotoxic effects of the compoundcis-tet

Cytotoxic effects of the compoundcis-tetraammine(oxalato)ruthenium(III) dithionate on K-562 human chronic myelogenous leukemia cells

✍ Flávia de Castro Pereira,Aliny Pereira de Lima… 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 482 KB